Group 1 - The innovative drug industry is showing signs of recovery, with factors such as increased investment and financing, record overseas expansion, and improved review efficiency potentially impacting biotechnology companies like Boan Biologics [1] Group 2 - Boan Biologics' stock price has fluctuated recently, with a range of 0.65% and a volatility of 6.06%. On February 10, the stock rose by 2.09% to 8.05 HKD, with a trading volume of 310 million HKD; on February 11, it closed flat at 7.80 HKD with reduced trading volume [2] Group 3 - Some institutions have set a target average price of 10.44 HKD for the company based on its innovative drug pipeline, indicating potential upside from the current price, but caution is advised due to uncertainties in profit forecasts [3]
博安生物股价波动，创新药复苏或带来间接影响